Bos Sci's Ion, Taxus Libert nab FDA approval for acute MI patients

Justine Varieur Cadet | | Health Imaging | Screening
Boston Scientific's Ion paclitaxel-eluting platinum chromium coronary stent system and Taxus Liberté paclitaxel-eluting coronary stent system have received FDA approval for use in patients experiencing acute MI (AMI).

Currently, they are the only drug-eluting stent (DES) systems in the U.S. with an approved indication to treat patients with AMI. The new indication is a result of FDA review of data from the Paclitaxel (Taxus) clinical program and HORIZONS-AMI trial.

The company said the Ion stent system incorporates a platinum chromium alloy designed specifically for coronary stenting and the acute performance of coronary stent implantation in the treatment of coronary artery disease.

Justine Varieur Cadet

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.